James Mulshine to Etoposide
This is a "connection" page, showing publications James Mulshine has written about Etoposide.
Connection Strength
0.080
-
Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer. 1994 Mar; 10 Suppl 1:S73-81.
Score: 0.029
-
Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). Cancer Res. 1989 May 01; 49(9):2390-7.
Score: 0.021
-
Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 1996 Mar; 14(3):806-13.
Score: 0.008
-
Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl. 1996; 24:173-85.
Score: 0.008
-
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994 Oct; 12(10):2022-34.
Score: 0.007
-
Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992 Jun; 53(6):992-8.
Score: 0.006